Company intelligence / Profile preview

108 Global

Hillsborough, North Carolina, United States108global.com ↗

Ownership: Private
Development stage: Other

Overview

108Labs has pioneered mammary cell agriculture to produce cell-cultured human milk containing key immune factors such as secretory IgA. The company is developing Colostrupedics™, a whole-human infant formula designed to closely mimic the composition and immune benefits of natural breastmilk. They are currently constructing what they describe as the world’s first autonomous factory for producing cultured human milk and antibodies.[2][3][4]

Therapeutic areas: Metabolic DisordersImmunology
Modalities: Cell therapy (mammary cell agriculture)Protein (secretory antibodies, secretory IgA)
Industry: Non-Drug Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on 108 Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 108 Global.

Explore the full profile